{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:41:14Z","timestamp":1791013274865,"version":"4.1.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"Background<\/jats:title>Spinal muscular atrophy (SMA) is an autosomal recessive disease, which can be classified into 4 types according to the symptom onset age and the highest physical developmental milestone. Among them, type 1 SMA is the most severe form that affects infants younger than 6 months. Permanent assisted ventilation is usually needed for infants with type 1 SMA before the age of 2 years due to the rapid progression of disease. Nusinersen can improve the motor function of SMA patients, but its effect on respiratory function varies. In the present study, we reported a case of child with type 1 SMA who was successfully weaned from the invasive respiratory support after nusinersen treatment.<\/jats:p><\/jats:sec>Case presentation<\/jats:title>A girl aged 6 years and 5 months was admitted for SMA in the Children\u2019s Hospital of Nanjing Medical University for 18 times. She received the first administration of nusinersen in November 2020 at the age of 5 years and 1 month. At the age of 6 years and 1 month following 6 loading doses, we tried to wean the child from the invasive ventilation for non-invasive respiratory support using a nasal mask. At present, the patient shows oxygen saturation (SpO2<\/jats:sub>) above 95% without ventilator support during the daytime, and no signs of dyspnea. A non-invasive home ventilator was used at nighttime for the sake of safety. The CHOP INTEND score increased by 11 points from the first loading dose to the sixth. She can now move her limbs against gravity, take in food orally and perform partial vocal function.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>We reported a child with type 1 SMA who was successfully weaned from the 2-years invasive ventilation after 6 loading doses, and now only need non-invasive ventilation 12\u2005h per day. It is suggested that even a late nusinersen treatment can improve respiratory and motor function in SMA patients, and wean them from mechanical ventilation, thus improve the quality of life and reduce the medical cost.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1097063","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T07:27:42Z","timestamp":1676446062000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful weaning from the invasive respiratory support after nusinersen treatment in a child with SMA type 1: A case report"],"prefix":"10.3389","volume":"11","author":[{"given":"Meiling","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"Finkel","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with sma type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","article-title":"Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from hungarian patients","volume":"27","author":"Szab\u00f3","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","article-title":"Nusinersen: a review in 5q spinal muscular atrophy","volume":"35","author":"Hoy","year":"2021","journal-title":"CNS Drugs"},{"key":"B5","first-page":"401","article-title":"Consensus statement for standard of pulmonary management in spinal muscular atrophy (2022 version)","volume":"6","year":"2022","journal-title":"Chin J Appl Clin Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ppul.25140","article-title":"Nusinersen for spinal muscular atrophy type 1: real-world respiratory experience","volume":"56","author":"Lavie","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ppul.25142","article-title":"Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen","volume":"56","author":"G\u00f3mez-Garc\u00eda de la Banda","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e15175","DOI":"10.1111\/ped.15175","article-title":"Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen","volume":"64","author":"Ergenekon","year":"2022","journal-title":"Pediatr Int"},{"key":"B11","first-page":"A02200100","article-title":"Nusinersen treatment of spinal muscular atrophy\u2014a systematic review","volume":"67","author":"Albrechtsen","year":"2020","journal-title":"Dan Med J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/ped.13931","article-title":"Respiratory assessment in a spinal muscular atrophy infant treated with nusinersen","volume":"61","author":"Ogawa","year":"2019","journal-title":"Pediatr Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/acn3.51321","article-title":"Successful weaning from mechanical ventilation in a patient with SMA type 1 treated with nusinersen","volume":"8","author":"Lee","year":"2021","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1097063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T07:27:46Z","timestamp":1676446066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1097063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":13,"alternative-id":["10.3389\/fped.2023.1097063"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1097063","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"1097063"}}